Biogelx created a Scientific Advisory Board (SAB) to provide scientific review and guidance to the company regarding research and development of its peptide-based hydrogels and bioinks.
The team met for the first time on the November 19th to discuss current status and to outline the scientific and commercial direction for the company in the next twelve to eighteen months.
The SAB will be chaired by Biogelx CEO, Alison Clayton, who has over twenty-five years’ experience in the industry, gaining experiences at businesses such as Quintiles, Aptuit and Eurofins before joining Biogelx in March 2020. Ms. Clayton said that: “I am excited to be joined in the Scientific Advisory Board by such distinguished and brilliant experts in their fields, who have joined in order to provide input and insight to Biogelx’s research and development strategy moving forward. I have no doubt that this group will push the company forward in the right direction.” She went on to say that “It is important that we have members with a broad range of experience and expertise in order to provide insight from all angles.”
The members of Biogelx’s SAB are:
Dr. Alison Clayton: Biogelx CEO.
Prof Rein Ulijn: Biogelx Founder & Board member. Director of the ASRC Sensor CAT (Center for Advanced Technology), Advanced Science Research Center, City University of New York (CUNY).
Dr Mhairi Rodgers: Biogelx Head of Operations.
Prof Matthew Dalby: Professor of Cell Engineering and co-director of the Centre for the Cellular Microenvironment at the University of Glasgow and director of the EPSRC/SFI lifETIME Centre for Doctoral Training.
Dr Manuel Salmeron-Sanchez: Professor of Biomedical Engineering and co-director of the Centre for the Cellular Microenvironment at the University of Glasgow.
Paul Smith: BioAscent CEO. Senior Executive with both General Management and Business Development experience in the pharmaceutical/CRO arena.